BioLine Rx (FRA:YP2) Cyclically Adjusted Book per Share: €106.80 (As of Mar. 2026)


FRA:YP2 BioLine Rx Ltd FRA:YP2
21 GF Score
Price €2.48
! 5 Warning Signs
View Full Analysis

What is BioLine Rx Cyclically Adjusted Book per Share?

BioLine Rx FRA:YP2 -2.36% 21 Cyclically Adjusted Book per Share is €106.80 as of Mar. 2026. GuruFocus rates FRA:YP2 with a GF Score™ of 21/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

BioLine Rx's adjusted book value per share for the three months ended in Mar. 2026 was €3.315. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €106.80 for the trailing ten years ended in Mar. 2026.

During the past 12 months, BioLine Rx's average Cyclically Adjusted Book Growth Rate was -29.20% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -20.20% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -18.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of BioLine Rx was -15.50% per year. The lowest was -20.20% per year. And the median was -16.50% per year.

As of today (2026-07-01), BioLine Rx's current stock price is €2.48. BioLine Rx's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was €106.80. BioLine Rx's Cyclically Adjusted PB Ratio of today is 0.02.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BioLine Rx was 0.25. The lowest was 0.01. And the median was 0.02.


BioLine Rx  (FRA:YP2) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

BioLine Rx's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.48/106.80
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of BioLine Rx was 0.25. The lowest was 0.01. And the median was 0.02.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


BioLine Rx Cyclically Adjusted Book per Share Related Terms


BioLine Rx Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for BioLine Rx's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLine Rx Cyclically Adjusted Book per Share Chart

BioLine Rx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 336.45 255.54 219.64 123.53 121.26

BioLine Rx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 178.80 125.16 123.34 121.26 106.80

FRA:YP2 vs VRTX, REGN, ALNY: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, BioLine Rx's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Cyclically Adjusted PB Ratio falls into.


FRA:YP2
21GF Score
BioLine Rx Ltd FRA:YP2
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLine Rx Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BioLine Rx's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=3.315/330.2130*330.2130
=3.315

Current CPI (Mar. 2026) = 330.2130.

BioLine Rx Quarterly Data

Book Value per Share CPI Adj_Book
201606 403.000 241.018 552.141
201609 365.968 241.428 500.553
201612 349.537 241.432 478.071
201703 324.214 243.801 439.127
201706 321.465 244.955 433.353
201709 284.609 246.819 380.771
201712 255.337 246.524 342.018
201803 224.616 249.554 297.215
201806 219.639 251.989 287.821
201809 193.228 252.439 252.760
201812 189.172 251.233 248.642
201903 168.510 254.202 218.898
201906 150.927 256.143 194.571
201909 140.680 256.759 180.926
201912 105.411 256.974 135.454
202003 86.577 258.115 110.760
202006 52.543 257.797 67.302
202009 42.636 260.280 54.092
202012 31.115 260.474 39.446
202103 50.989 264.877 63.566
202106 52.826 271.696 64.203
202109 50.986 274.310 61.377
202112 50.551 278.802 59.873
202203 48.305 287.504 55.481
202206 44.706 296.311 49.821
202209 36.462 296.808 40.566
202212 31.205 296.797 34.718
202303 23.753 301.836 25.986
202306 12.635 305.109 13.675
202309 7.611 307.789 8.166
202312 6.695 306.746 7.207
202403 6.634 312.332 7.014
202406 6.501 314.175 6.833
202409 3.832 315.301 4.013
202412 5.770 315.605 6.037
202503 5.186 319.799 5.355
202506 4.082 322.561 4.179
202509 3.825 324.800 3.889
202512 3.571 324.054 3.639
202603 3.315 330.213 3.315

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of €106.80 mean?
BioLine Rx (FRA:YP2) has a Cyclically Adjusted Book per Share of €106.80 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BioLine Rx and its competitors.
Is BioLine Rx's Cyclically Adjusted Book per Share too high?
BioLine Rx's current Cyclically Adjusted Book per Share is €106.80. Overall, BioLine Rx has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's Cyclically Adjusted Book per Share compare to VRTX and REGN?
BioLine Rx's Cyclically Adjusted Book per Share of €106.80 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on BioLine Rx and its competitors. BioLine Rx's current Cyclically Adjusted Book per Share is €106.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (FRA:YP2) has a current Cyclically Adjusted Book per Share of €106.80. The current Cyclically Adjusted Book per Share is €106.80. BioLine Rx's overall GF Score™ is 21/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For BioLine Rx (FRA:YP2), the current Cyclically Adjusted Book per Share is €106.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BioLine Rx Business Description

Other Exchanges BLRX:USABLRX:Israel
Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
21GF Score

Get the complete analysis for FRA:YP2

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.48
Price